Defiance Launches the First Autism-Impact ETF (Ticker: ASD), Donating Profits to Autism Causes *

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The ASD ETF is the first U.S.-listed ETF combining an autism-focused thematic index and a binding adviser-level commitment to donate net advisory profits to autism-related causes.

  60% confidence

• Defiance ETFs was founded in 2018 and is a leading thematic and income-focused ETF issuer managing more than 75 ETFs and over $13.4 billion in assets under management.

  60% confidence

• Defiance plans to donate 100% of the ETF's net profits in its first two years to autism-focused nonprofit organizations and a minimum of 50% of annual net profits thereafter.

  60% confidence

• There are currently no FDA-approved medications addressing the core symptoms of autism spectrum disorder.

  60% confidence

• Products based on the VettaFi Autism Impact Index are not sponsored, endorsed, sold, or promoted by VettaFi, and VettaFi makes no representation regarding the advisability of trading in such products.

  60% confidence

• As parents of a profoundly autistic child, this launch is deeply personal to our family. Families impacted by autism face challenges every single day, and after experiencing that firsthand, we became committed to helping drive greater awareness, innovation, research, and support for the autism community.

  60% confidence

Cited in these Via News reports

• Gilead Buys Ouro Medicines, Gives Spin-Off $500M to Build Global Inflammation Pipeline →
• Gilead and Europe's Lakefront Close $500M Ouro Deal in Cross-Atlantic Biotech Push →